Company Overview of Abmaxis, Inc.
Abmaxis, Inc., a biopharmaceutical company, engages in the discovery, optimization, and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. It offers Abmaxis in-silico Immunization (AISIM), an antibody engineering technology platform, which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The company was incorporated in 2000 and is based in Santa Clara, California. As of May 9, 2006, Abmaxis, Inc. operates as a subsidiary of Merck & Co. Inc.
3303 Octavius Drive
Santa Clara, CA 95054
Founded in 2000
Key Executives for Abmaxis, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Sponsored Financial Commentaries
To contact Abmaxis, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.